Software Treatment for Actively Reducing Severity of ADHD - Follow Up

The study will be a blinded (investigators and outcome assessors), randomized (from parent
study Akili-001R), parallel group, follow-up study of the sustained effects of 4-weeks of
treatment with either AKL-T01 (EVO Multi) game-based digital therapy or AKL-T09 (EVO Words)
game-based digital therapy.

The trial will consist of 4 visits: Screening (to be conducted at the same time as the
end-of-study visit for the parent study Akili-001R), FU-Day 28 visit (conducted in clinic),
and FU-Day 56 and FU-Day 84 visits (conducted remotely via electronically captured parent
reported outcomes).

Inclusion Criteria:

- Completed Akili Study Akili-001R including all clinical assessments at DAY28 per the
study protocol

- Ability to comply with all the testing and requirements per this protocol

Exclusion Criteria:

- Participant is currently considered a suicide risk in the opinion of the Investigator,
has previously made a suicide attempt, or has a prior history of, or is currently
demonstrating active suicidal ideation or self-injurious behavior as measured by
C-SSRS at screening

- Participant has demonstrated clinically significant deterioration in functioning as
assessed by PI and other study staff that would contraindicate continued participation
in the follow-up study